Company Overview - Kewah Bioengineering Co., Ltd. is located at 1189 Qinzhu North Road, Xuhui District, Shanghai, established on November 22, 1981, and listed on July 21, 2004. The company specializes in the research, production, and sales of in vitro clinical immunodiagnostic reagents, in vitro clinical chemical diagnostic reagents, nucleic acid diagnostic reagents, genetic engineering drugs, and automated diagnostic instruments [1]. Financial Performance - As of June 30, 2025, Kewah Bio reported a revenue of 794 million yuan, a year-on-year decrease of 12.65%. The net profit attributable to shareholders was -133 million yuan, reflecting a significant year-on-year decline of 154.37% [2]. - Cumulative cash dividends since the A-share listing amount to 1.694 billion yuan, with 309 million yuan distributed over the past three years [3]. Stock Performance - On October 15, Kewah Bio's stock price increased by 2.04%, reaching 6.49 yuan per share, with a trading volume of 19.29 million yuan and a turnover rate of 0.58%. The total market capitalization stands at 3.338 billion yuan [1]. - Year-to-date, the stock price has risen by 2.85%, with a 1.41% increase over the last five trading days, a 3.85% decrease over the last 20 days, and a 0.76% decrease over the last 60 days [1]. Shareholder Information - As of June 30, 2025, the number of Kewah Bio shareholders is 42,200, a decrease of 0.84% from the previous period. The average number of circulating shares per person is 12,176, which has increased by 0.84% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the eighth largest, holding 2.5849 million shares, a reduction of 420,000 shares compared to the previous period [3]. Business Segmentation - The revenue composition of Kewah Bio includes 49.76% from agency products, 46.73% from self-produced products, and 3.51% from other sources [1]. - The company operates within the pharmaceutical and biological industry, specifically in medical devices and in vitro diagnostics, and is involved in concepts such as gene sequencing, blood products, anti-influenza, pet economy, and monkeypox [1].
科华生物涨2.04%,成交额1929.24万元,主力资金净流入107.37万元